Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer  

作　　者：Mi Mi Chenyang Ye Ying Yuan 

机构地区：[1]Department of Medical Oncology,Key Laboratory of Cancer Prevention and Intervention,the Second Affiliated Hospital of Zhejiang University School of Medicine,310009,Hangzhou,Zhejiang,China [2]Cancer Center,Zhejiang University,310058,Hangzhou,Zhejiang,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第11期3989-3991,共3页信号转导与靶向治疗（英文）

基　　金：National Natural Science Foundation of China(82103102 to C.Y.Y.);Provincial Key R&D Program of Zhejiang Province(2021C03125 to Y.Y.).

摘　　要：In a prospective phase 2 study recently published in The New England Journal of Medicine,Cercek et al.investigated the efficacy of the programmed death 1(PD-1)inhibitor dostarlimab in patients with mismatch repair–deficient(dMMR),locally advanced rectal cancer(LARC).The work aimed to present preliminary evidence for the revolutionary therapeutic transition from neoadjuvant chemotherapy/radiotherapy followed by surgery to immunotherapy followed by nonoperative management in this subgroup of patients.

关 键 词：OPERATIVE al. RECTAL 

分 类 号：R735.37[医药卫生—肿瘤]